Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of 225Ac-PSMA I&T in metastatic prostate cancer
NL-OMON59229Phase 1Recruiting
- Sponsor
- Erasmus MC
- Start
- Feb 2022
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Peptides
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of actinium-225 PSMA I&T in prostate cancer (PCa), sponsored by Erasmus MC. Started Feb 2022; status: recruiting.
02
Drugs
actinium-225 PSMA I&T
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON59229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59229.